Get the Stockscreener App
185.95
2.28%
4.15
Overview
News
Price History
Option Chain
Why AZN Down?
Discussions
Forecast
Stock Split
Dividend History
Astrazeneca Plc stock is traded at $185.95, with a volume of 2.34M.
It is up +2.28% in the last 24 hours and up +2.60% over the past month.
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
See More
Previous Close:
$181.80
Open:
$184.02
24h Volume:
2.34M
Relative Volume:
1.21
Market Cap:
$288.38B
Revenue:
$60.48B
Net Income/Loss:
$10.40B
P/E Ratio:
55.85
EPS:
3.3297
Net Cash Flow:
$8.05B
1W Performance:
+0.15%
1M Performance:
+2.60%
6M Performance:
+106.20%
1Y Performance:
+157.01%
1-Day Range:
$184.02
$186.12
1-Week Range:
$174.60
$186.12
52-Week Range:
$68.61
$212.71
Astrazeneca Plc Stock (AZN) Company Profile
Name
Astrazeneca Plc
Sector
Industry
Phone
-
Address
-
Compare AZN vs LLY, JNJ, ABBV, MRK
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca Plc
|
185.95 | 281.95B | 60.48B | 10.40B | 8.05B | 3.3297 |
LLY
Lilly Eli Co
|
1,131.42 | 1.00T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
232.77 | 549.25B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
227.23 | 397.42B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
120.79 | 297.02B | 65.51B | 8.93B | 14.12B | 3.5532 |
Astrazeneca Plc Stock (AZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-27-26 | Initiated | Citigroup | Buy |
| Oct-27-25 | Resumed | Jefferies | Buy |
| Oct-16-25 | Downgrade | Deutsche Bank | Hold → Sell |
| Apr-15-25 | Initiated | Exane BNP Paribas | Outperform |
| Feb-13-25 | Upgrade | UBS | Neutral → Buy |
| Feb-12-25 | Initiated | Morgan Stanley | Overweight |
| Nov-20-24 | Upgrade | UBS | Sell → Neutral |
| Nov-06-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Sep-13-24 | Downgrade | Deutsche Bank | Hold → Sell |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-16-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Feb-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Sell |
| Jan-03-24 | Downgrade | Jefferies | Buy → Hold |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Sep-25-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-12-23 | Upgrade | UBS | Neutral → Buy |
| Jul-05-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Sep-15-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Sep-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-29-22 | Upgrade | Argus | Hold → Buy |
| Jun-14-22 | Downgrade | UBS | Buy → Neutral |
| Feb-11-22 | Upgrade | DZ Bank | Sell → Hold |
| Dec-07-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-12-21 | Resumed | JP Morgan | Overweight |
| Apr-12-21 | Downgrade | Argus | Buy → Hold |
| Mar-16-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Upgrade | UBS | Neutral → Buy |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Dec-07-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-30-20 | Upgrade | UBS | Sell → Neutral |
| Nov-11-20 | Upgrade | HSBC Securities | Reduce → Hold |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Nov-22-19 | Initiated | SVB Leerink | Outperform |
| Oct-25-19 | Upgrade | Liberum | Hold → Buy |
| Apr-02-19 | Downgrade | UBS | Neutral → Sell |
| Feb-05-19 | Initiated | Exane BNP Paribas | Outperform |
| Jan-25-19 | Upgrade | Shore Capital | Hold → Buy |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Aug-16-18 | Downgrade | Jefferies | Buy → Hold |
| Mar-19-18 | Upgrade | Jefferies | Hold → Buy |
| Feb-06-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-05-18 | Reiterated | Bernstein | Outperform |
| Jan-18-18 | Reiterated | Leerink Partners | Mkt Perform |
| Dec-29-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-16-17 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-25-17 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Sep-22-17 | Upgrade | Bernstein | Mkt Perform → Outperform |
View All
Astrazeneca Plc Stock (AZN) Latest News
AstraZeneca chief warns group could withhold new drugs in Europe - Financial Times
AstraZeneca Broadens US Growth Push - marketscreener.com
AstraZeneca advances Friday, outperforms market - MarketWatch
AstraZeneca plc stock (GB0009895292): Share price edges higher after 3.1% move and valuation focus - AD HOC NEWS
AstraZeneca (AZN) Stock: Bernstein Identifies 37% Upside Potential in Overlooked Segment - Blockonomi
NYSE Content Update: AstraZeneca Celebrates Largest Transfer in NYSE History – Company Announcement - Financial Times
Bernstein: Why AstraZeneca’s biggest growth opportunity is being overlooked By Investing.com - Investing.com Nigeria
Worldwide Healthcare Trust outperforms benchmark; praises AstraZeneca - marketscreener.com
Why is AstraZeneca trending right now - Kalkine Media
AstraZeneca PLC (AZN) Shares Surge 3.1% -- What GF Score of 83 T - GuruFocus
AstraZeneca advances Thursday, outperforms market - MarketWatch
IEFA: Why This Fund Is One of the Best International ETFs - The Motley Fool
AstraZeneca plc stock (GB0009895292): oncology growth and sector backdrop ahead of next earnings - AD HOC NEWS
AstraZeneca (AZN) CEO awarded 101,495 shares on AZPSP vesting - Stock Titan
AstraZeneca Sees Encouraging Survival Trend In Liver Cancer Trial - Yahoo
Can AstraZeneca's Expanding Cancer Portfolio Sustain Momentum? - Yahoo Finance
Leading Bank maintains sell on AstraZeneca at 11,500p as ASCO glow fails to resolve key pipeline questions - Proactive financial news
AstraZeneca PLC Share PriceAZN, RNS News, Articles, Quotes, & Charts (LON:AZN) - Proactive Investors
AstraZeneca plc stock (GB0009895292): shares soften after SERENA-6 breast cancer data update - AD HOC NEWS
AstraZeneca Highlights Sustained Survival Benefit In Advanced Breast Cancer Study - Benzinga
AstraZeneca’s camizestrant shows survival benefit in breast cancer By Investing.com - Investing.com South Africa
AstraZeneca slips Tuesday, underperforms market - MarketWatch
AstraZeneca’s (AZN) CARES Phase III Clinical Programme Fails to Meet Primary End Point - Yahoo Finance
AstraZeneca Says Combination Liver Cancer Therapy Meets Primary Endpoint in Phase 3 Study - marketscreener.com
AZN Technical Analysis | Trend, Signals & Chart Patterns | ASTRAZENECA PLC (NYSE:AZN) - ChartMill
AstraZeneca’s FDA Setback: A Temporary Hiccup or a Bigger Story? - Kalkine Media
AstraZeneca PLC (AZN) Stock Down 3.2% but Still Overvalued -- GF Score: 84/100 - GuruFocus
ASTRAZENECA : Gets a Buy rating from JP Morgan - marketscreener.com
AstraZeneca PLC (AZN) Presents at American Society of Clinical Oncology (ASCO) Annual Meeting 2026Slideshow - Seeking Alpha
AstraZeneca : Biographies (ASCO2026 biographies 20260601) - marketscreener.com
AstraZeneca PLC Stock (AZN) Closed Down by 3.17% on Jun 1: Facts Behind the Movement - TradingKey
ASCO26: AstraZeneca’s AZD-3470 demonstrates PRMT5 inhibitor safety for cHL patients - Clinical Trials Arena
AstraZeneca falls Monday, underperforms market - MarketWatch
AstraZeneca reports total voting rights of 1.55 billion shares By Investing.com - Investing.com India
AstraZeneca admits 14,120 shares from employee schemes - Investing.com
AstraZeneca reports total voting rights of 1.55 billion shares - Investing.com
AstraZeneca (AZN) admits 14,120 new employee scheme shares to LSE - Stock Titan
AstraZeneca admits 14,120 shares from employee schemes By Investing.com - Investing.com Canada
AstraZeneca (AZN) reports 1.55B total voting rights as of May 2026 - Stock Titan
ASCO 2026: A quiet conference for European pharma, but AstraZeneca and Roche both have work to do - Proactive financial news
ASTRAZENECA : Barclays gives a Buy rating - marketscreener.com
AstraZeneca aims for a new blockbuster run in cardio disease - Pharma Voice
AstraZeneca hails Imfinzi and Imjudo liver cancer trial results - London South East
AstraZeneca PLC (AZN) Stock Analysis: Evaluating A Promising 20.91% Upside Potential - DirectorsTalk Interviews
FDA approves AstraZeneca’s Imfinzi-BCG combination for NMIBC therapy - Pharmaceutical Technology
Imfinzi plus Imjudo combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolisation-eligible unresectable liver cancer in EMERALD-3 Phase III trial - AstraZeneca
AstraZeneca PLC stock (US6549022043): London shares edge higher after CARES Phase III update - AD HOC NEWS
ASTRAZENECA : Buy rating from JP Morgan - marketscreener.com
AstraZeneca plc stock (GB0009895292): LSE shares edge higher after CARES Phase III update - AD HOC NEWS
AstraZeneca | Pharmaceuticals, Vaccines, & Facts | Britannica Money - Britannica
AstraZeneca gets FDA nod for new hypertension drug Baxfendy - MSN
Astrazeneca Plc Stock (AZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.51%
1.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):